In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research ...

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports. They currently ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a ...

On Friday, Revolution Medicines Inc (RVMD) stock saw a modest uptick, ending the day at $60.44 which represents a slight increase of $1.34 or 2.27% from the prior close of $59.1. The stock opened at ...

Warning! GuruFocus has detected 6 Warning Signs with RVMD. Revolution Medicines Inc (NASDAQ:RVMD), a clinical-stage precision ...

Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...

Revolution Medicines Inc (RVMD) reports promising clinical progress and robust cash reserves, despite increased R&D and ...

Tango Therapeutics (TNGX) stock plunged 28% Wednesday after the company announced updates on several drug candidates and released its Q3 earnings report. Read more here.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.66% ...

Revolution Medicines Inc (NASDAQ:RVMD) is set to release its Q3 2024 earnings on Nov 6, 2024. The consensus estimate for Q3 2024 revenue is $0.75 million, and the earnings are expected to come in at ...